Orion Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Orion Oyj şirketinin toplam hissedar öz sermayesi €924.4M ve toplam borcu €256.8M olup, bu da borç-öz sermaye oranını 27.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €1.6B ve €683.3M dir. Orion Oyj 'in FAVÖK'ü €379.6M faiz karşılama oranı 180.8 dur. Şirketin €190.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

27.8%

Borç/özkaynak oranı

€256.80m

Borç

Faiz karşılama oranı	180.8x
Nakit	€190.10m
Eşitlik	€924.40m
Toplam yükümlülükler	€683.30m
Toplam varlıklar	€1.61b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OFK 'nin kısa vadeli varlıkları ( €975.7M ) kısa vadeli yükümlülüklerini ( €403.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: OFK şirketinin kısa vadeli varlıkları ( €975.7M ) uzun vadeli yükümlülüklerini ( €279.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OFK 'nin net borç/öz sermaye oranı ( 7.2% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: OFK şirketinin borç/öz sermaye oranı son 5 yılda 0.4% seviyesinden 27.8% seviyesine yükseldi.

Borç Kapsamı: OFK 'nin borcu işletme nakit akışı ( 98.7% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: OFK 'in borcuna ilişkin faiz ödemeleri EBIT ( 180.8 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Orion Oyj Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Now 20% undervalued after recent price drop

Third quarter 2024 earnings released: EPS: €1.14 (vs €0.44 in 3Q 2023)

Orion Oyj Updates Earnings Guidance for the Full Year 2024

Orion Corporation Decides to Terminate the ODM-111 Development Program

Upcoming dividend of €0.81 per share

Now 21% undervalued

President recently sold €420k worth of stock

Insider recently sold €440k worth of stock

Second quarter 2024 earnings released: EPS: €0.37 (vs €0.26 in 2Q 2023)

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025

Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint

Orion Oyj Revises Earnings Guidance for the Year 2024

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

First quarter 2024 earnings released

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Upcoming dividend of €0.81 per share

Full year 2023 earnings released: EPS: €1.55 (vs €2.49 in FY 2022)

Full year 2023 earnings released: EPS: €1.55 (vs €2.49 in FY 2022)

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

New major risk - Earnings quality

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Orion Oyj to Report First Half, 2024 Results on Jul 18, 2024

Second quarter 2023 earnings released

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

Now 22% undervalued after recent price drop

Independent Chairman recently sold €76k worth of stock

First quarter 2023 earnings released

Upcoming dividend of €1.60 per share at 3.7% yield

Insider recently sold €233k worth of stock

Full year 2022 earnings released: EPS: €2.49 (vs €1.38 in FY 2021)

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Orion Oyj Announces Executive Changes

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Second quarter 2022 earnings released

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Orion Oyj Announces Executive Changes

First quarter 2022 earnings released

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Upcoming dividend of €1.50 per share

Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide

Investor sentiment improved over the past week

Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orion Oyj Provides Earnings Outlook for the Year 2022

Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS €0.40 (vs €0.54 in 2Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers

Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion

Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion

First quarter 2021 earnings released: EPS €0.42 (vs €0.48 in 1Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Upcoming Dividend of €1.50 Per Share

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

New 90-day low: €35.81

Revenue misses expectations

Finansal Durum Analizi